Neuroblastoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Neuroblastoma – Pipeline Review, H2 2017’, provides an overview of the Neuroblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuroblastoma

The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects

The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuroblastoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuroblastoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ability Pharmaceuticals SL

Actuate Therapeutics Inc

Advanced Accelerator Applications SA

Alissa Pharma

Ampio Pharmaceuticals Inc

APAvadis Biotechnologies Srl

APEIRON Biologics AG

AstraZeneca Plc

Autolus Ltd

Bayer AG

Bellicum Pharmaceuticals Inc

Bexion Pharmaceuticals LLC

BioLineRx Ltd

Biotec Pharmacon ASA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cancer Prevention Pharmaceuticals Inc

Cebiotex SL

Celgene Corp

Celldex Therapeutics Inc

Cielo Therapeutics Inc

Cleveland BioLabs Inc

CorMedix Inc

Curis Inc

Cyclacel Pharmaceuticals Inc

DEKK-TEC Inc

EnGeneIC Ltd

Epizyme Inc

Errant Gene Therapeutics LLC

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Green Cross Cell Corp

Ignyta Inc

Ipsen SA

Juno Therapeutics Inc

Lindis Biotech GmbH

Loxo Oncology Inc

MabVax Therapeutics Holdings Inc

MacroGenics Inc

MediaPharma SRL

Merck & Co Inc

Morphogenesis Inc

Novartis AG

Novogen Ltd

OGD2 Pharma SAS

Pfizer Inc

Phylogica Ltd

Progenics Pharmaceuticals Inc

Recombio SL

Ribomic Inc

Sapience Therapeutics Inc

Sareum Holdings Plc

Sierra Oncology Inc

Sorrento Therapeutics Inc

Syros Pharmaceuticals Inc

Tiltan Pharma Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Neuroblastoma - Overview 10

Neuroblastoma - Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Pipeline by Universities/Institutes 17

Products under Development by Companies 20

Products under Development by Universities/Institutes 26

Neuroblastoma - Therapeutics Assessment 28

Assessment by Target 28

Assessment by Mechanism of Action 34

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Neuroblastoma - Companies Involved in Therapeutics Development 43

Ability Pharmaceuticals SL 43

Actuate Therapeutics Inc 43

Advanced Accelerator Applications SA 43

Alissa Pharma 44

Ampio Pharmaceuticals Inc 44

APAvadis Biotechnologies Srl 45

APEIRON Biologics AG 45

AstraZeneca Plc 45

Autolus Ltd 46

Bayer AG 46

Bellicum Pharmaceuticals Inc 47

Bexion Pharmaceuticals LLC 47

BioLineRx Ltd 48

Biotec Pharmacon ASA 48

Boehringer Ingelheim GmbH 49

Bristol-Myers Squibb Co 49

Cancer Prevention Pharmaceuticals Inc 49

Cebiotex SL 50

Celgene Corp 50

Celldex Therapeutics Inc 51

Cielo Therapeutics Inc 51

Cleveland BioLabs Inc 52

CorMedix Inc 52

Curis Inc 53

Cyclacel Pharmaceuticals Inc 53

DEKK-TEC Inc 54

EnGeneIC Ltd 54

Epizyme Inc 54

Errant Gene Therapeutics LLC 55

F. Hoffmann-La Roche Ltd 55

GlaxoSmithKline Plc 56

Green Cross Cell Corp 56

Ignyta Inc 57

Ipsen SA 57

Juno Therapeutics Inc 58

Lindis Biotech GmbH 58

Loxo Oncology Inc 59

MabVax Therapeutics Holdings Inc 59

MacroGenics Inc 59

MediaPharma SRL 60

Merck & Co Inc 60

Morphogenesis Inc 61

Novartis AG 61

Novogen Ltd 62

OGD2 Pharma SAS 62

Pfizer Inc 63

Phylogica Ltd 63

Progenics Pharmaceuticals Inc 64

Recombio SL 64

Ribomic Inc 65

Sapience Therapeutics Inc 65

Sareum Holdings Plc 65

Sierra Oncology Inc 66

Sorrento Therapeutics Inc 66

Syros Pharmaceuticals Inc 67

Tiltan Pharma Ltd 67

Neuroblastoma - Drug Profiles 69

1-B7 - Drug Profile 69

31-F9 - Drug Profile 71

9-ING41 - Drug Profile 72

abexinostat hydrochloride - Drug Profile 74

ABTL-0812 - Drug Profile 77

ACY-1035 - Drug Profile 80

ACY-957 - Drug Profile 81

afatinib dimaleate - Drug Profile 84

ALKCAR-15 - Drug Profile 99

ALKCAR-48 - Drug Profile 100

ALKCAR-53 - Drug Profile 101

ALKCAR-58 - Drug Profile 102

AMB-8LK - Drug Profile 103

AMXT-1501 + eflornithine hydrochloride - Drug Profile 104

APN-301 - Drug Profile 106

AT-69 - Drug Profile 108

BACPT-DP - Drug Profile 109

bevacizumab - Drug Profile 110

BGA-002 - Drug Profile 122

Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile 123

BL-8040 - Drug Profile 124

BPX-701 - Drug Profile 137

BXQ-350 - Drug Profile 139

CBL-0137 - Drug Profile 141

CCT-244747 - Drug Profile 145

CCT-68127 - Drug Profile 147

CEB-01 - Drug Profile 148

Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 149

Cellular Immunotherapy for Neuroblastoma - Drug Profile 151

Cellular Immunotherapy for Neuroblastoma - Drug Profile 152

Cellular Immunotherapy for Oncology - Drug Profile 153

Cellular Immunotherapy to Target CD3 and GD2 for Neuroblastoma - Drug Profile 155

Cellular Immunotherapy to Target GD2 and CD56 for Solid Tumors - Drug Profile 156

Cellular Immunotherapy to Target GD2 for Melanoma and Neuroblastoma - Drug Profile 157

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 158

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 159

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 160

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 161

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 162

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 163

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 164

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 165

Celyvir - Drug Profile 166

ceritinib - Drug Profile 167

CG-1521 - Drug Profile 174

CMD-501 - Drug Profile 175

crizotinib - Drug Profile 176

CYC-065 - Drug Profile 183

dactolisib tosylate - Drug Profile 187

danusertib - Drug Profile 189

dinutuximab beta - Drug Profile 191

DS-1647 - Drug Profile 194

Edotreotide Labeled Yttrium 90 - Drug Profile 195

eflornithine - Drug Profile 197

eh-8B6 - Drug Profile 199

enoblituzumab - Drug Profile 200

ensartinib - Drug Profile 203

entrectinib - Drug Profile 206

fimepinostat - Drug Profile 215

FSEC - Drug Profile 220

Gene Therapy to Activate GAS1 for Oncology - Drug Profile 221

GSK-525762 - Drug Profile 222

HSV-1716 - Drug Profile 224

ICA-1 - Drug Profile 228

Immuncell-LC - Drug Profile 229

ImmuneFx - Drug Profile 231

iobenguane sulfate I 131 - Drug Profile 232

ipilimumab + nivolumab - Drug Profile 236

irinotecan hydrochloride - Drug Profile 246

irinotecan hydrochloride + TBio-02 - Drug Profile 258

JCAR-023 - Drug Profile 260

Kid EDV - Drug Profile 261

KOS-1803 - Drug Profile 262

KTN-0125TEI - Drug Profile 264

larotrectinib - Drug Profile 265

lorlatinib - Drug Profile 272

lutetium Lu 177 dotatate - Drug Profile 275

M-606 - Drug Profile 282

M-7085 - Drug Profile 283

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 284

Monoclonal Antibody Conjugate to Target CD56 for Neuroblastoma - Drug Profile 286

Monoclonal Antibody Conjugates to Target Glypican-2 for Neuroblastoma - Drug Profile 287

Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 288

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 289

MPTEM-1ADC - Drug Profile 291

NCE-001 - Drug Profile 292

nifurtimox - Drug Profile 293

OGD-201 - Drug Profile 294

olaparib - Drug Profile 295

Oncolytic Virus for Neuroblastoma - Drug Profile 309

Oncolytic Virus for Neuroblastoma - Drug Profile 310

Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor - Drug Profile 311

ORP-008 - Drug Profile 312

paclitaxel albumin bound - Drug Profile 313

pazopanib hydrochloride - Drug Profile 326

pembrolizumab - Drug Profile 335

Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 397

racotumomab - Drug Profile 398

RBM-001 - Drug Profile 400

ribociclib succinate - Drug Profile 401

RNAi Oligonucleotides for Neuroblastoma - Drug Profile 409

RSF-701 - Drug Profile 411

SAR-020106 - Drug Profile 412

SAR-4 - Drug Profile 414

selumetinib sulfate - Drug Profile 416

SF-1126 - Drug Profile 424

SF-2523 - Drug Profile 427

Small Molecules 3 for Oncology - Drug Profile 429

Small Molecules to Inhibit ALK for Oncology - Drug Profile 430

Soluble Beta Glucan - Drug Profile 431

SRA-737 - Drug Profile 434

ST-36 - Drug Profile 438

SY-1365 - Drug Profile 439

Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile 443

Synthetic Peptide to Inhibit N-Myc for Oncology - Drug Profile 444

taurolidine - Drug Profile 445

tazemetostat - Drug Profile 446

TL-118 - Drug Profile 458

TR-100 - Drug Profile 460

TRBS-07 - Drug Profile 461

Trilexium - Drug Profile 462

Vaccine for Neuroblastoma - Drug Profile 464

Vaccine for Neuroblastoma - Drug Profile 466

Vaccine for Neuroblastoma - Drug Profile 467

Vaccine to Target GD2 and GD3 for Neuroblastoma - Drug Profile 468

Vaccine to Target WT1 for Oncology - Drug Profile 469

vemurafenib - Drug Profile 470

VIMO-001 - Drug Profile 478

Neuroblastoma - Dormant Projects 479

Neuroblastoma - Discontinued Products 482

Neuroblastoma - Product Development Milestones 483

Featured News & Press Releases 483

Appendix 496

Methodology 496

Coverage 496

Secondary Research 496

Primary Research 496

Expert Panel Validation 496

Contact Us 496

Disclaimer 497

List of Tables

List of Tables

Number of Products under Development for Neuroblastoma, H2 2017 20

Number of Products under Development by Companies, H2 2017 22

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 23

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 24

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 25

Number of Products under Development by Universities/Institutes, H2 2017 26

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 28

Products under Development by Companies, H2 2017 29

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 30

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 31

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 32

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 33

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 34

Products under Development by Universities/Institutes, H2 2017 35

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 36

Number of Products by Stage and Target, H2 2017 38

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 39

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 40

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 41

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 42

Number of Products by Stage and Mechanism of Action, H2 2017 44

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 45

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 46

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 47

Number of Products by Stage and Route of Administration, H2 2017 49

Number of Products by Stage and Molecule Type, H2 2017 51

Neuroblastoma – Pipeline by Ability Pharmaceuticals SL, H2 2017 52

Neuroblastoma – Pipeline by Actuate Therapeutics Inc, H2 2017 52

Neuroblastoma – Pipeline by Advanced Accelerator Applications SA, H2 2017 53

Neuroblastoma – Pipeline by Alissa Pharma, H2 2017 53

Neuroblastoma – Pipeline by Ampio Pharmaceuticals Inc, H2 2017 53

Neuroblastoma – Pipeline by APAvadis Biotechnologies Srl, H2 2017 54

Neuroblastoma – Pipeline by APEIRON Biologics AG, H2 2017 54

Neuroblastoma – Pipeline by AstraZeneca Plc, H2 2017 55

Neuroblastoma – Pipeline by Autolus Ltd, H2 2017 55

Neuroblastoma – Pipeline by Bayer AG, H2 2017 56

Neuroblastoma – Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 56

Neuroblastoma – Pipeline by Bexion Pharmaceuticals LLC, H2 2017 57

Neuroblastoma – Pipeline by BioLineRx Ltd, H2 2017 57

Neuroblastoma – Pipeline by Biotec Pharmacon ASA, H2 2017 57

Neuroblastoma – Pipeline by Boehringer Ingelheim GmbH, H2 2017 58

Neuroblastoma – Pipeline by Bristol-Myers Squibb Co, H2 2017 58

Neuroblastoma – Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017 59

Neuroblastoma – Pipeline by Cebiotex SL, H2 2017 59

Neuroblastoma – Pipeline by Celgene Corp, H2 2017 60

Neuroblastoma – Pipeline by Celldex Therapeutics Inc, H2 2017 60

Neuroblastoma – Pipeline by Cielo Therapeutics Inc, H2 2017 61

Neuroblastoma – Pipeline by Cleveland BioLabs Inc, H2 2017 61

Neuroblastoma – Pipeline by CorMedix Inc, H2 2017 62

Neuroblastoma – Pipeline by Curis Inc, H2 2017 62

Neuroblastoma – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 63

Neuroblastoma – Pipeline by DEKK-TEC Inc, H2 2017 63

Neuroblastoma – Pipeline by EnGeneIC Ltd, H2 2017 63

Neuroblastoma – Pipeline by Epizyme Inc, H2 2017 64

Neuroblastoma – Pipeline by Errant Gene Therapeutics LLC, H2 2017 64

Neuroblastoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 65

Neuroblastoma – Pipeline by GlaxoSmithKline Plc, H2 2017 65

Neuroblastoma – Pipeline by Green Cross Cell Corp, H2 2017 66

Neuroblastoma – Pipeline by Ignyta Inc, H2 2017 66

Neuroblastoma – Pipeline by Ipsen SA, H2 2017 67

Neuroblastoma – Pipeline by Juno Therapeutics Inc, H2 2017 67

Neuroblastoma – Pipeline by Lindis Biotech GmbH, H2 2017 67

Neuroblastoma – Pipeline by Loxo Oncology Inc, H2 2017 68

Neuroblastoma – Pipeline by MabVax Therapeutics Holdings Inc, H2 2017 68

Neuroblastoma – Pipeline by MacroGenics Inc, H2 2017 69

Neuroblastoma – Pipeline by MediaPharma SRL, H2 2017 69

Neuroblastoma – Pipeline by Merck & Co Inc, H2 2017 70

Neuroblastoma – Pipeline by Morphogenesis Inc, H2 2017 70

Neuroblastoma – Pipeline by Novartis AG, H2 2017 71

Neuroblastoma – Pipeline by Novogen Ltd, H2 2017 71

Neuroblastoma – Pipeline by OGD2 Pharma SAS, H2 2017 72

Neuroblastoma – Pipeline by Pfizer Inc, H2 2017 72

Neuroblastoma – Pipeline by Phylogica Ltd, H2 2017 73

Neuroblastoma – Pipeline by Progenics Pharmaceuticals Inc, H2 2017 73

Neuroblastoma – Pipeline by Recombio SL, H2 2017 74

Neuroblastoma – Pipeline by Ribomic Inc, H2 2017 74

Neuroblastoma – Pipeline by Sapience Therapeutics Inc, H2 2017 74

Neuroblastoma – Pipeline by Sareum Holdings Plc, H2 2017 75

Neuroblastoma – Pipeline by Sierra Oncology Inc, H2 2017 75

Neuroblastoma – Pipeline by Sorrento Therapeutics Inc, H2 2017 76

Neuroblastoma – Pipeline by Syros Pharmaceuticals Inc, H2 2017 76

Neuroblastoma – Pipeline by Tiltan Pharma Ltd, H2 2017 77

Neuroblastoma – Dormant Projects, H2 2017 488

Neuroblastoma – Dormant Projects, H2 2017 (Contd..1), H2 2017 489

Neuroblastoma – Dormant Projects, H2 2017 (Contd..2), H2 2017 490

Neuroblastoma – Discontinued Products, H2 2017 491

List of Figures

List of Figures

Number of Products under Development for Neuroblastoma, H2 2017 20

Number of Products under Development by Companies, H2 2017 21

Number of Products under Development by Universities/Institutes, H2 2017 26

Number of Products by Top 10 Targets, H2 2017 37

Number of Products by Stage and Top 10 Targets, H2 2017 37

Number of Products by Top 10 Mechanism of Actions, H2 2017 43

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 43

Number of Products by Routes of Administration, H2 2017 48

Number of Products by Stage and Routes of Administration, H2 2017 48

Number of Products by Top 10 Molecule Types, H2 2017 50

Number of Products by Stage and Top 10 Molecule Types, H2 2017 50

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports